CEO turned informant: How the FDA built a case against executives promising cheap medications

CNBC
CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
Read the full story
This is a short summary. The complete article is published by CNBC.
Continue at CNBC

Headline and summary aggregated from public news feeds. For information only — not financial advice.